Recombinant human cathepsin L (Halozyme Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human cathepsin L (Halozyme Therapeutics)
Drug Alias Name重组人组织蛋白酶L - Halozyme TherapeuticsrHuCAT-LHTI-501
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionCathepsin L modulators
TargetsCathepsin L
Therapy Area/IndicationsCellulitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHalozyme Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHalozyme Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCellulitis

Other Information

ATC CodeN/A
Related LinksN/A